StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M) ($M)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

QuarterlyAnnual
Latest, Q3 2026
496
Period ended Sep 30, 2026
Change on a year earlier
+6.7%
465 in Q3 2025
History
44 quarters
Since Q4 2015
Sources
41
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026496+6.7%SEC Filing (0001628280-26-066601) ↗
Q2 2026Jun 30, 2026509+7.4%SEC Filing (0001628280-26-048377) ↗
Q1 2026Mar 31, 2026486+10.0%SEC Filing (0001628280-26-025365) ↗
Q4 2025Dec 31, 2025496+8.8%SEC Filing (0001628280-26-002982) ↗
Q3 2025Sep 30, 2025465+5.4%SEC Filing (0001628280-25-045049) ↗
Q2 2025Jun 30, 2025474+5.6%SEC Filing (0001628280-25-035135) ↗
Q1 2025Mar 31, 2025442+1.6%SEC Filing (0001628280-25-017924) ↗
Q4 2024Dec 31, 2024456+5.6%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 2024441+4.8%SEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 2024449-0.4%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 2024435+9.0%SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 2023432+10.5%SEC Filing (0001628280-24-002009) ↗
Q3 2023Sep 30, 2023421+7.1%SEC Filing (0001628280-23-034544) ↗
Q2 2023Jun 30, 2023451+6.1%SEC Filing (0001628280-23-025156) ↗
Q1 2023Mar 31, 2023399-2.7%SEC Filing (0001628280-23-012020) ↗
Q4 2022Dec 31, 2022391-12.5%SEC Filing (0001628280-23-001516) ↗

Breakdown

What makes up vascular division (xience des, esprit btk dissolving stent, diamondback 360 atherectomy) — international revenue ($m)

Cite this data

StockData. (2026). Abbott Laboratories Vascular Division (XIENCE DES, Esprit BTK Dissolving Stent, Diamondback 360 Atherectomy) — International Revenue ($M) ($M), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-vasc-rev-intl

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.